Catalyst Pharmaceuticals, Inc.CPRXNASDAQ
Loading
CPRX Revenue Growth (YoY Quarterly)•+7.61%
Stock Alarm Pro
Growth Metrics
Latest: Q4 2025vs Q3 2025
Revenue GrowthGross Profit GrowthEBITDA GrowthOperating Income GrowthNet Income GrowthEPS GrowthEPS Diluted GrowthWeighted Average Shares GrowthWeighted Average Shares Diluted GrowthDividends per Share Growth
+7.61%
-7.7pp
+15.28%
+2.8pp
+12.12%
-45.9pp
-1.59%
-31.8pp
-5.79%
-26.1pp
-10.64%
-26.9pp
-9.09%
-29.1pp
+2.00%
-1.1pp
+0.77%
-0.6pp
+0.00%
+0.0pp
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +28.26% | +43.56% | +19.44% | +15.31% | +7.61% |
| Gross Profit Growth | +26.82% | +43.63% | +8.67% | +12.49% | +15.28% |
| EBITDA Growth | +42.23% | +99.22% | +23.67% | +58.03% | +12.12% |
| Operating Income Growth | +50.73% | +133.60% | +22.22% | +30.17% | -1.59% |
| Net Income Growth | +60.53% | +143.77% | +27.73% | +20.28% | -5.79% |
| EPS Growth | +42.42% | +135.00% | +22.86% | +16.22% | -10.64% |
| EPS Diluted Growth | +41.94% | +136.84% | +24.24% | +20.00% | -9.09% |
| Weighted Average Shares Growth | +12.35% | +3.99% | +3.37% | +3.09% | +2.00% |
| Weighted Average Shares Diluted Growth | +11.01% | +2.88% | +2.32% | +1.34% | +0.77% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +27.37% | +88.08% | +11.17% | -55.49% | -36.66% |
| Free Cash Flow Growth | +32.74% | +89.25% | +11.15% | -55.33% | -36.63% |
| Receivables Growth | +22.06% | +19.17% | +15.77% | +83.24% | +95.86% |
| Inventory Growth | +24.91% | -0.88% | +3.53% | +40.03% | +90.19% |
| Asset Growth | +81.11% | +40.55% | +37.59% | +36.22% | +30.00% |
| Book Value per Share Growth | +66.97% | +36.05% | +36.06% | +35.06% | +28.57% |
| Debt Growth | -10.37% | -10.87% | -11.40% | -11.97% | -12.58% |
| R&D Expense Growth | +92.60% | +50.60% | +46.00% | -19.09% | -52.42% |
| SG&A Expenses Growth | +5.13% | -0.06% | +12.81% | +3.47% | +20.88% |
1 / 4